Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A16649 | 28266614 | Sci Rep | A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. | 2017 | Details |
| A16650 | 28265826 | Dig Dis Sci | Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients. | 2017 | Details |
| A16657 | 28260907 | Ther Clin Risk Manag | Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients. | 2017 | Details |
| A16662 | 28257594 | Hepatol Res | Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis. | 2017 | Details |
| A16665 | 28256569 | Mod Pathol | Aggressive non-alcoholic steatohepatitis following rapid weight loss and/or malnutrition. | 2017 | Details |
| A16672 | 28253211 | Eur J Gastroenterol Hepatol | Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation. | 2017 | Details |
| A16673 | 28253210 | Eur J Gastroenterol Hepatol | The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study. | 2017 | Details |
| A16674 | 28252464 | Eur J Gastroenterol Hepatol | Hyperuricemia is not associated with severity of liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. | 2017 | Details |
| A16676 | 28251449 | Inflammation | A20 Attenuates Liver Fibrosis in NAFLD and Inhibits Inflammation Responses. | 2017 | Details |
| A16678 | 28250338 | Biosci Trends | Key role of liver sinusoidal endothelial cells in liver fibrosis. | 2017 | Details |
| A16679 | 28250290 | Intern Med | The Relationship between the Growth Hormone/Insulin-like Growth Factor System and the Histological Features of Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A16683 | 28249038 | PLoS One | Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. | 2017 | Details |
| A16688 | 28243042 | Ann Gastroenterol | Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease. | 2016 | Details |
| A16692 | 28241279 | JAMA Intern Med | Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. | 2017 | Details |
| A16701 | 28235154 | Liver Int | Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. | 2017 | Details |
| A16704 | 28233737 | Ann Hepatol | Perspectives on NASH Histology: Cellular Ballooning. | 2017 | Details |
| A16706 | 28232454 | Am J Physiol Gastrointest Liver Physiol | A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. | 2017 | Details |
| A16707 | 28231800 | Lipids Health Dis | Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. | 2017 | Details |
| A16708 | 28231412 | Liver Int | Impact of family history of metabolic traits on severity of non-alcoholic steatohepatitis related cirrhosis: A cross-sectional study. | 2017 | Details |
| A16712 | 28229316 | Obes Surg | Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A16713 | 28225987 | Arch Endocrinol Metab | Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist? | 2017 | Details |
| A16715 | 28225568 | J Magn Reson Imaging | Liver histology and diffusion-weighted MRI in children with nonalcoholic fatty liver disease: A MAGNET study. | 2017 | Details |
| A16730 | 28219123 | Hepatol Res | Identification of core gene networks and hub genes associated with progression of non-alcoholic fatty liver disease by RNA sequencing. | 2017 | Details |
| A16732 | 28218651 | Int J Mol Sci | Proteome Characteristics of Non-Alcoholic Steatohepatitis Liver Tissue and Associated Hepatocellular Carcinomas. | 2017 | Details |
| A16736 | 28216979 | World J Gastroenterol | Association between endotoxemia and histological features of nonalcoholic fatty liver disease. | 2017 | Details |
| A16738 | 28215516 | Dig Liver Dis | AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. | 2017 | Details |
| A16743 | 28213091 | Toxicol Appl Pharmacol | Convergence of hepcidin deficiency, systemic iron overloading, heme accumulation, and REV-ERBα/β activation in aryl hydrocarbon receptor-elicited hepatotoxicity. | 2017 | Details |
| A16745 | 28212548 | Oncotarget | Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model. | 2017 | Details |
| A16758 | 28202906 | Sci Rep | BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. | 2017 | Details |
| A16760 | 28199729 | Clin Endocrinol (Oxf) | Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort. | 2017 | Details |
| A16761 | 28195363 | Hepatology | Liver fibrosis scores predict liver disease mortality in the United States population. | 2017 | Details |
| A16763 | 28195177 | Am J Gastroenterol | Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. | 2017 | Details |
| A16764 | 28194671 | Dig Dis Sci | Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis. | 2017 | Details |
| A16767 | 28193580 | J Nutr Biochem | Astaxanthin inhibits inflammation and fibrosis in the liver and adipose tissue of mouse models of diet-induced obesity and nonalcoholic steatohepatitis. | 2016 | Details |
| A16768 | 28192190 | J Hepatol | β7-Integrin and MAdCAM-1 play opposing roles during the development of non-alcoholic steatohepatitis. | 2017 | Details |
| A16771 | 28190475 | Phytomedicine | Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor. | 2016 | Details |
| A16776 | 28184213 | Front Endocrinol (Lausanne) | Loss of Hepatic CEACAM1: A Unifying Mechanism Linking Insulin Resistance to Obesity and Non-Alcoholic Fatty Liver Disease. | 2017 | Details |
| A16783 | 28179090 | Dig Liver Dis | Protective role of soluble receptor for advanced glycation end-products in patients with non-alcoholic fatty liver disease. | 2017 | Details |
| A16788 | 28177674 | Can J Physiol Pharmacol | Exercise restores bioavailability of hydrogen sulfide and promotes autophagy influx in livers of mice fed with high-fat diet. | 2017 | Details |
| A16792 | 28174796 | Rom J Morphol Embryol | Non-alcoholic fatty liver disease - clinical and histopathological aspects. | 2016 | Details |
| A16793 | 28170108 | Hepatology | Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease. | 2017 | Details |
| A16798 | 28167322 | J Hepatol | NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. | 2017 | Details |
| A16811 | 28159867 | J Lipid Res | Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferase. | 2017 | Details |
| A16817 | 28155087 | Curr Gastroenterol Rep | The Association Between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A16826 | 28144390 | World J Hepatol | Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. | 2017 | Details |
| A16827 | 28144388 | World J Hepatol | Hepatic structural enhancement and insulin resistance amelioration due to AT1 receptor blockade. | 2017 | Details |
| A16828 | 28144387 | World J Hepatol | From the liver to the heart: Cardiac dysfunction in obese children with non-alcoholic fatty liver disease. | 2017 | Details |
| A16832 | 28139562 | Ter Arkh | [The informative value of non-invasive liver fibrosis markers in patients with nonalcoholic fatty liver disease]. | 2017 | Details |
| A16835 | 28138308 | Int J Med Sci | Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients. | 2017 | Details |
| A16840 | 28133774 | Hepatology | Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis. | 2017 | Details |
| A16841 | 28133479 | Gastroenterol Res Pract | Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. | 2017 | Details |
| A16846 | 28130788 | Hepatology | Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. | 2017 | Details |
| A16847 | 28128372 | Food Funct | The hepatoprotective effect of Phyllanthus emblica L. fruit on high fat diet-induced non-alcoholic fatty liver disease (NAFLD) in SD rats. | 2017 | Details |
| A16849 | 28127545 | Can J Gastroenterol Hepatol | Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp. | 2017 | Details |
| A16855 | 28125073 | Clin Transl Gastroenterol | The Association Between IGF-1 Levels and the Histologic Severity of Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A16857 | 28124507 | Obesity (Silver Spring) | Fatty liver promotes fibrosis in monkeys consuming high fructose. | 2017 | Details |
| A16863 | 28123933 | Mol Metab | A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. | 2016 | Details |
| A16870 | 28116873 | Endocrinol Metab (Seoul) | The SCAP/SREBP Pathway: A Mediator of Hepatic Steatosis. | 2017 | Details |
| A16875 | 28115795 | Mediators Inflamm | The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications. | 2017 | Details |
| A16887 | 28110063 | Int Immunopharmacol | Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation. | 2017 | Details |
| A16888 | 28109892 | Free Radic Biol Med | Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. | 2017 | Details |
| A16891 | 28109005 | Hepatology | The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. | 2017 | Details |
| A16892 | 28108233 | J Hepatol | Murine CD103+ dendritic cells protect against steatosis progression towards steatohepatitis. | 2017 | Details |
| A16897 | 28106137 | Sci Rep | Ameliorative effects of Compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats. | 2017 | Details |
| A16899 | 28104990 | World J Gastroenterol | Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. | 2017 | Details |
| A16907 | 28100008 | Hepatology | Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. | 2017 | Details |
| A16919 | 28092182 | Exp Biol Med (Maywood) | An estrogen receptor β-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors. | 2017 | Details |
| A16928 | 28089429 | Rev Gastroenterol Mex | Diagnosis and quantification of fibrosis, steatosis, and hepatic siderosis through multiparametric magnetic resonance imaging. | 2017 | Details |
| A16933 | 28086768 | BMC Complement Altern Med | Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers. | 2017 | Details |
| A16939 | 28082803 | World J Gastroenterol | Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. | 2016 | Details |
| A16946 | 28079667 | Eur J Gastroenterol Hepatol | Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis. | 2017 | Details |
| A16950 | 28077318 | Exp Mol Pathol | Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. | 2017 | Details |
| A16954 | 28075394 | Nutrients | Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B. | 2017 | Details |
| A16955 | 28075092 | Am Fam Physician | Diabetes Mellitus: Management of Gastrointestinal Complications. | 2016 | Details |
| A16963 | 28073183 | Hepatology | A liver-specific long noncoding RNA with a role in cell viability is elevated in human nonalcoholic steatohepatitis. | 2017 | Details |
| A16972 | 28068223 | Cell Metab | Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. | 2016 | Details |
| A16973 | 28068221 | Cell Metab | Devilish Effects of Taz in Nonalcoholic Steatohepatitis. | 2016 | Details |
| A16979 | 28065744 | Clin Res Hepatol Gastroenterol | Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2017 | Details |
| A16985 | 28063221 | J Cell Physiol | Novel circulating biomarkers for non-alcoholic fatty liver disease: A systematic review. | 2017 | Details |
| A16986 | 28063004 | Mol Cell Biochem | Tubulin alpha 8 is expressed in hepatic stellate cells and is induced in transformed hepatocytes. | 2017 | Details |
| A16987 | 28062946 | J Gastroenterol | Upregulated absorption of dietary palmitic acids with changes in intestinal transporters in non-alcoholic steatohepatitis (NASH). | 2017 | Details |
| A16993 | 28058076 | Gastroenterology Res | Non-Alcoholic Fatty Pancreatic Disease: A Review of Literature. | 2016 | Details |
| A17002 | 28052636 | Liver Int | Non-pharmacological interventions in non-alcoholic fatty liver disease patients. | 2017 | Details |
| A17003 | 28052629 | Liver Int | Pathology of non-alcoholic fatty liver disease. | 2017 | Details |
| A17004 | 28052626 | Liver Int | Therapies in non-alcoholic steatohepatitis (NASH). | 2017 | Details |
| A17009 | 28051792 | Ann Hepatol | Management strategies for liver fibrosis. | 2017 | Details |
| A17011 | 28051126 | Sci Rep | Cytochrome P450-2E1 promotes fast food-mediated hepatic fibrosis. | 2017 | Details |
| A17012 | 28050580 | Data Brief | Microarray data and pathway analyses for primary human activated hepatic stellate cells compared to HepG2 human hepatoma cells. | 2016 | Details |
| A17022 | 28039158 | Am J Physiol Gastrointest Liver Physiol | Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis. | 2016 | Details |
| A17031 | 29984130 | Curr Hepatol Rep | Natural History of NAFLD/NASH. | 2017 | Details |
| A17042 | 28033294 | Medicine (Baltimore) | The expression of thymosin β4 in chronic hepatitis B combined nonalcoholic fatty liver disease. | 2016 | Details |
| A17045 | 28030556 | PLoS One | Hepatocyte Hypoxia Inducible Factor-1 Mediates the Development of Liver Fibrosis in a Mouse Model of Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A17047 | 28029021 | Endocrinol Metab (Seoul) | Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A17048 | 28028821 | Aliment Pharmacol Ther | Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. | 2016 | Details |
| A17053 | 28027586 | Hepatology | Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. | 2017 | Details |
| A17056 | 28019064 | Hepatol Res | Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. | 2017 | Details |
| A17072 | 28008583 | Exp Clin Endocrinol Diabetes | EndoBarrier Gastrointestinal Liner in Type 2 Diabetic Patients Improves Liver Fibrosis as Assessed by Liver Elastography. | 2016 | Details |
| A17075 | 28006772 | Cell Physiol Biochem | Involvement of Sphingosine 1-Phosphate in Palmitate-Induced Non-Alcoholic Fatty Liver Disease. | 2016 | Details |
| A17077 | 28003718 | J Clin Exp Hepatol | Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience. | 2016 | Details |
| A17081 | 28001263 | Rev Assoc Med Bras (1992) | Current management of non-alcoholic fatty liver disease. | 2016 | Details |